Warning letter
Mississippi Blood Services, Inc.: warning letter of Jul 2, 2002
FDA warning letter UCM144998 · New Orleans District Office
Key facts
| Reference number | UCM144998 |
|---|---|
| Company | Mississippi Blood Services, Inc. |
| Subject | CGMP Regulations for Blood & Blood Components/CGMP for Finished Pharmaceuticals |
| Issue date | Jul 2, 2002 |
| Posted date | Jul 2, 2002 |
| Issuing office | New Orleans District Office |
| Product type | Biologics |
| CFR sections cited | 211.100, 606.100, 606.160, 606.171, 640.25, 606.20(b), 606.60(a), 606.100(b)(7), 606.100(b)(13), 606.140(a), 606.60(b) |
| Country | 3 |
| Inspection city | Flowood |
| Inspection ZIP | 39232-7661 |
| Inspection start date | Mar 25, 2002 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: